Ecrins Therapeutics

Ecrins Therapeutics est membre de Lyonbiopôle

General information

BIOPOLIS, 5 av. du Grand Sablon

38700 La Tronche

Incorporated in: 2010/07/21

Number of employees: 6

Turnover: €70000 (in 2016)


More information

 

Main activity

Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel small molecule drugs that are intended as cancer therapies. The company aims to develop these potential new drugs from the preclinical phase to Phase II clinical proof of concept.


Funding

Looking for funding: Yes

Nature of funding searches: Founded in 2010 with a vision to fight cancer, Ecrins Therapeutics is also committed to delivering value to its shareholders. We are interested in the investment and/or development partners, who could speed up the progress of our  technology to the market place. Currently we are seeking 4 mln euros to take our main product ET-D5 into Phase I/II clinical trials.

Public funding obtained: Canceropôle CLARA, 2009, 478 K€; MESR/OSEO, "Emergence", 2009, 26 K€; MESR/OSEO, “Création-Développement” , 2010, 220 K€; Canceropôle CLARA, 2012, 15 K€; Eurostars 1.7 M€; FUI 2.1 M€  

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Oncology


Activities
Therapeutics, Pharma or Biotech - CRO


Technologies
Cell Therapy - cell biology - Biobanking - Screening services